A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene.

Abstract:

PURPOSE AND METHODS:MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). The multidrug resistance-associated protein (MRP) gene is thought to play an important role in MDR in lung cancer. To investigate whether MS-209 could also overcome MRP-mediated MDR, we examined the effect of the compound using a cytotoxicity assay on MDR1 gene-negative drug-selected MDR and wildtype lung cancer cells with various levels of MRP gene expression. The effects of MS-209 were compared with those of verapamil (VER) and cyclosporin A (CsA). The level of MRP gene expression in the cells was evaluated semiquantitatively by RT-PCR. For vincristine (VCR), intracellular accumulation of [3H]-VCR was measured with or without MS-209. RESULTS:In MDR UMCC-1/VP small-cell lung carcinoma cell line, 5 microM of MS-209 and VER enhanced the cytotoxicity of etoposide, doxorubicin (DOX) and VCR more than twofold, and completely reversed the resistance to VCR. The mean reversing effects of MS-209 on DOX and VCR were significantly stronger than those of VER and CsA. In wildtype non-small-cell lung carcinoma cells, the effects of MS-209 were almost equal to those of VER and CsA. The effect of these three agents correlated with the level of MRP gene expression. The MS-209-induced increase in intracellular accumulation of VCR was proportional to the level of MRP gene expression in these cells. CONCLUSION:Our results indicate that MS-209 is a potentially useful drug that can overcome MRP-mediated intrinsic and acquired MDR in human lung cancer.

authors

Narasaki F,Oka M,Fukuda M,Nakano R,Ikeda K,Takatani H,Terashi K,Soda H,Yano O,Nakamura T,Doyle LA,Tsuruo T,Kohno S

doi

10.1007/s002800050681

subject

Has Abstract

pub_date

1997-01-01 00:00:00

pages

425-32

issue

5

eissn

0344-5704

issn

1432-0843

journal_volume

40

pub_type

杂志文章
  • Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.

    abstract:PURPOSE:We assessed the clinical efficacy and safety of mitoxantrone hydrochloride which has been used as an anticancer drug in our hospital to treat breast cancer patients since 1993. METHODS:A group of 23 patients with breast cancer were given one course of the following regimen every 3 weeks: mitoxantrone hydrochlo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0586-z

    authors: Katsumata K,Tomioka H,Kusama M,Aoki T,Koyanagi Y

    更新日期:2003-07-01 00:00:00

  • FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.

    abstract:OBJECTIVE:To investigate the effects of FSTL1-mediated NF-κB signaling pathway on cisplatin (DDP) sensitivity of EOC cells. METHODS:FSTL1 expression was determined in epithelial ovarian cancer (EOC) tissues and corresponding adjacent tissues using immunohistochemistry. SKOV3 and SKOV3/DDP cells were transfected and gr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-020-04215-9

    authors: Liu YK,Jia YJ,Liu SH,Ma J

    更新日期:2021-01-03 00:00:00

  • Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines.

    abstract:PURPOSE:Tetrandrine (Tet), a bis-benzylisoquinoline alkaloid that was isolated from the dried root of Hang-Fang-Chi (Stephania tetrandra S. Moore), is well known as processing a marked antitumor effect in vitro and in vivo. The aim of this study was to assess the interaction between tetrandrine and chemotherapeutic age...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0416-9

    authors: Wei J,Liu B,Wang L,Qian X,Ding Y,Yu L

    更新日期:2007-10-01 00:00:00

  • Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.

    abstract:BACKGROUND:Few clinical phase II studies using non-platinum doublet as adjuvant chemotherapy following complete resection of non-small-cell lung cancer (NSCLC) have been published, so this clinical study was designed to evaluate the toxicity profile and efficacy of the non-platinum doublet of docetaxel (DOC) + gemcitab...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0391-6

    authors: Kawamura M,Eguchi K,Izumi Y,Yamato Y,Koike T,Sakaguchi H,Hada E,Kobayashi K

    更新日期:2007-09-01 00:00:00

  • Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

    abstract:PURPOSE:Oral administration of 9-nitrocamptothecin (9NC), and the formation of its metabolite 9-aminocamptothecin (9AC), may be associated with high interpatient and intrapatient variability. Therefore, we evaluated the plasma pharmacokinetics and urine recovery of 9NC administered on three different schedules as part ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-004-0835-9

    authors: Jung LL,Ramanathan RK,Egorin MJ,Jin R,Belani CP,Potter DM,Strychor S,Trump DL,Walko C,Fakih M,Zamboni WC

    更新日期:2004-12-01 00:00:00

  • Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB.

    abstract:PURPOSE:The ErbB family members are protein tyrosine kinases, which play a crucial role in the signal transduction pathways that regulate key cellular functions. Overexpression of the ErbB family members is associated with oncogenicity, metastatic potential, cell proliferation, apoptosis, angiogenesis, and prognosis in...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-011-1748-z

    authors: Fu XH,Li J,Huang JJ,Zheng S,Zhang SZ

    更新日期:2011-12-01 00:00:00

  • Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.

    abstract:BACKGROUND:Pre-clinical activity of SSG against melanoma and renal cancer has been identified recently although the drug's mechanism of action and activity against tumors of additional histological-types remain undefined. METHODS:The effects of SSG and SSG combination with other agents on DU145 human prostate carcinom...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0378-3

    authors: Li J,Lindner DJ,Farver C,Borden EC,Yi T

    更新日期:2007-08-01 00:00:00

  • The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.

    abstract::Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00255274

    authors: Lu K,Loo TL

    更新日期:1980-01-01 00:00:00

  • Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo.

    abstract::Increasing the expression of human multidrug resistance (MDR) 1 gene in bone marrow cells to prevent or circumvent bone morrow toxicity from chemotherapy agent is a high priority of dose intensification protocols. In this study, we have used a tumor-bearing model to investigate the chemoprotection effect of MDR1 gene ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-0144-y

    authors: Guo CB,Li YC,Jin XQ

    更新日期:2006-07-01 00:00:00

  • Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.

    abstract::Studies are described in which a new folate analogue, edatrexate (EDX), in combination with the vinca alkaloids, vinblastine (VBL), navelbine (NVB) or vindesine (DVA) was evaluated against E0771 mammary adenocarcinoma, T241 fibrosarcoma and the Lewis lung tumor. Each of the four agents when given individually to anima...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685901

    authors: Otter GM,Sirotnak FM

    更新日期:1994-01-01 00:00:00

  • A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.

    abstract:BACKGROUND:Head and neck squamous carcinoma (HNSCC) is a chemotherapy-sensitive tumour, but this sensitivity is not reflected in an impact on survival. The study of new drugs is therefore indicated. Pirarubicin (4'-O-tetrahydropyranyl-doxorubicin) has a higher preclinical index than doxorubicin, with low cardiotoxicity...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00686275

    authors: De Mulder PH,Cappelaere P,Cognetti F,Verweij J,Schornagel JH,Vermorken JB,Kirkpatrick A,Lefebvre JL

    更新日期:1994-01-01 00:00:00

  • Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.

    abstract:BACKGROUND:Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic chemotherapy. In vitro, aprepitant is a moderate inhibitor of the CYP3A4 enzyme, which is involved in the clearance of several chemotherapeutic agents. In this st...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s00280-004-0946-3

    authors: Nygren P,Hande K,Petty KJ,Fedgchin M,van Dyck K,Majumdar A,Panebianco D,de Smet M,Ahmed T,Murphy MG,Gottesdiener KM,Cocquyt V,van Belle S

    更新日期:2005-06-01 00:00:00

  • A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.

    abstract:PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3458-7

    authors: Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

    更新日期:2017-12-01 00:00:00

  • Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.

    abstract::1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma. The drugs were given orally at 2--4 days intervals for a total of ten doses. 5-FU wa...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254027

    authors: Tsuruo T,Iida H,Naganuma K,Tsukagoshi S,Sakurai Y

    更新日期:1980-01-01 00:00:00

  • Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.

    abstract:PURPOSE:To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. PATIENTS AND METHODS:A total of 104 consecutive patients were enrolled for treatment with FA 100 mg/m(2) ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-002-0495-6

    authors: Francini G,Petrioli R,Messinese S,Pozzessere D,Marsili S,Correale P,Sabatino M,Fiaschi AI

    更新日期:2002-10-01 00:00:00

  • Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.

    abstract::In the original article, corresponding author's given name and family name are flipped. It should be "Siqing Fu" rather than "Fu Siqing". ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 已发布勘误

    doi:10.1007/s00280-016-3002-1

    authors: Fu S,Culotta KS,Falchook GS,Hong DS,Myers AL,Zhang YP,Naing A,Janku F,Hou MM,Kurzrock R

    更新日期:2016-04-01 00:00:00

  • Polymorphic tandem repeat sequences of the thymidylate synthase gene correlates with cellular-based sensitivity to fluoropyrimidine antitumor agents.

    abstract:PURPOSE:Thymidylate synthase (TS) is one of the target molecules for the antitumor effects of fluoropyrimidine drugs. The cellular thymidylate synthase level is one of the determining factors for the antitumor activity of fluoropyrimidines. TYMS, which encodes TS, has been reported to possess 28-bp tandem repeat sequen...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-1018-z

    authors: Yawata A,Kim SR,Miyajima A,Kubo T,Ishida S,Saito Y,Nakajima Y,Katori N,Matsumoto Y,Fukuoka M,Ohno Y,Ozawa S,Sawada J

    更新日期:2005-11-01 00:00:00

  • Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.

    abstract:PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-020-04213-x

    authors: Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

    更新日期:2021-01-05 00:00:00

  • Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.

    abstract:PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050854

    authors: de Vos D,Slee PH,Briggs RJ,Stevenson D

    更新日期:1998-01-01 00:00:00

  • Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.

    abstract:PURPOSE:Some clinical studies on etoposide (Eto) have shown marked schedule dependency of the effect (starting at about 1 mg/l) and toxicity (over about 10 mg/l) whereas other studies have not confirmed these results. What are the conclusions we can draw from these inconsistent results when developing new low-dose (LD)...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-001-0418-y

    authors: Würthwein G,Boos J

    更新日期:2002-04-01 00:00:00

  • Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.

    abstract::Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and go...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03787-5

    authors: Thorpe D,Sultani M,Stringer A

    更新日期:2019-05-01 00:00:00

  • The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

    abstract::Dose fractionation is known to reduce the toxicity of ifosfamide and also results in an increased production of alkylating metabolites. Administration by slow infusion using the convenience of ambulatory pumps is therefore of interest. We used HPLC to investigate the stability of ifosfamide in aqueous solution (either...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF02897261

    authors: Radford JA,Margison JM,Swindell R,Lind MJ,Wilkinson PM,Thatcher N

    更新日期:1990-01-01 00:00:00

  • Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential.

    abstract:BACKGROUND:Rapidly dividing tumor cells have an increased demand for nutrients to support their characteristic unabated growth; this demand is met by an increased availability of nutrients such as amino acids through vasculogenesis and by the enhanced cellular entry of nutrients through the upregulation of specific tra...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1453-3

    authors: Trojel-Hansen C,Erichsen KD,Christensen MK,Jensen PB,Sehested M,Nielsen SJ

    更新日期:2011-07-01 00:00:00

  • In vitro succinate dehydrogenase chemosensitivity of gastric carcinoma--relationship to DNA content.

    abstract::Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was micros...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686250

    authors: Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

    更新日期:1992-01-01 00:00:00

  • Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

    abstract::The mechanisms of cytotoxicity, cellular drug uptake, intracellular drug distribution, cellular pharmacokinetics, formation of arabinofuranosylcytosine triphosphate (ara-CTP), and DNA incorporation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC), a new lipophilic derivative of arabinofuranosylcytosine (ara-C)...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685798

    authors: Horber DH,Schott H,Schwendener RA

    更新日期:1995-01-01 00:00:00

  • Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.

    abstract:PURPOSE:To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach. METHODS:A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years). Prednisolo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-003-0602-3

    authors: Petersen KB,Jusko WJ,Rasmussen M,Schmiegelow K

    更新日期:2003-06-01 00:00:00

  • Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents.

    abstract:PURPOSE:There is a need to find novel oestrogen receptor (ER) ligands that antagonize oestrogen action in the reproductive tissues and would therefore have therapeutic potential in oestrogen-dependent tumours. We tested novel ER ligands in both breast and endometrial cells to profile agonism/antagonism in these oestrog...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800000259

    authors: Nuttall ME,Pendrak I,Emery JG,Nadeau DP,Fisher PW,Nicholson TA,Zhu Y,Suva LJ,Kingsbury WD,Gowen M

    更新日期:2001-05-01 00:00:00

  • Adjunction of a MEK inhibitor to Vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury.

    abstract:INTRODUCTION:A combined therapy MEK inhibitor, Cobimetinib (CB) and BRAF inhibitor, Vemurafenib (VMF), results in an improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma. VMF skin adverse effects attributed to ERK paradoxical activation are decreased by the adjunction of CB...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3300-2

    authors: Teuma C,Pelletier S,Amini-Adl M,Perier-Muzet M,Maucort-Boulch D,Thomas L,Laville M,Fouque D,Dalle S

    更新日期:2017-05-01 00:00:00

  • Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

    abstract:BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0463-1

    authors: Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

    更新日期:2002-08-01 00:00:00

  • Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells.

    abstract:OBJECTIVES:To investigate the effects and potential mechanisms of gambogic acid (GA), a naturally occurring anticancer agent, on the expression and regulation of telomerase in human gastric carcinoma cells. METHODS:GA-induced inhibition of cell proliferation was evaluated by the commonly employed MTT assay on two huma...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-0177-2

    authors: Yu J,Guo QL,You QD,Lin SS,Li Z,Gu HY,Zhang HW,Tan Z,Wang X

    更新日期:2006-10-01 00:00:00